Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published: November 2011
No. of Pages: 126
Price: $ 3500

GlobalData, the industry analysis specialist, has released its new report, “Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global ADHD therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010, three drugs namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine) were approved in the US. The acceptance for Vyvanse was high in the US, in spite of its high treatment cost in comparison to that of existing drugs. Thus, high acceptance for Vyvanse has resulted in the significant growth of the market. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, due to which the US market declined. This has resulted in the decline in the global ADHD market in 2009.

Between 2010 and 2018, the global ADHD market is expected to grow at a CAGR of 8%. The growth rate is similar across the US and European countries, but it is slightly high in Japan (18.4%). This difference across geographical markets exists because of the variation in the approval date for some of the drugs in the US, Europe and Japan. In the US, major nonstimulant therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved; whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse, being a safer nonstimulant, its acceptance across Europe would be high and considered as growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612 and RIT124D have similar therapeutic mode of action as that of exiting drugs which will not impact the market significantly.

During this forecast period, patents for various drugs such as Adderall XR, Daytrana, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to expire. However, the losses due to expiry of these patents would be compensated by new drugs entering the market such as Vyvanse and Intuniv. Thus, the global ADHD market will show a steady growth from 2010 to 2018.

Scope
The report provides information on the key drivers and challenges of the ADHD market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ADHD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as norepinephrine-dopamine reuptake inhibitor, selective alpha2A-adrenergic receptor agonist, serotonin-norepinephrine-dopamine reuptake inhibitor, selective serotonin (5-HT1)-dopamine antagonist, serotonin (5-HT1A and 5-HT1B) receptor agonists, highly selective norepinephrine reuptake inhibitor (NRI), antagonist of alcohol-metabolic effects, dopamine partial agonist, alpha 4 beta 2 neuronal nicotinic receptor (NNR) agonists, dopamine antagonist, alpha7 NNR agonist., serotonin and norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitors (SSRIs), dopamine (D2) receptors and serotonin type 2 (5-HT2) receptor agonist, alpha 3 beta 2 and alpha 4 beta 2 NNR antagonist, histamine H3 receptor antagonist, selective alpha2A-adrenergic receptor agonist, histamine H3 autoreceptor antagonist, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor modulators, specific phosphodiesterase 1 (PDE1) inhibitor, dopamine uptake inhibitors and serotonin (5-HT6) receptor antagonist.
- Analysis of the current and future competition in the global ADHD market. Key market players covered are Curemark LLC, Johnson & Johnson, Nextwave Pharmaceuticals, Novartis AG and Shire Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market.
- Analysis of key recent licensing and partnership agreements in ADHD market.

Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ADHD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global ADHD market landscape? – Identify, understand and capitalize.